ARCH PATHOL LAB MED:高通量全自动免疫分析仪检测乙肝病毒感染的比较

2020-05-30 MedSci原创 MedSci原创

已经引进乙肝病毒血清学标志物的高通量自动化免疫分析仪,但还没有与现有系统进行比较。

已经引进乙肝病毒血清学标志物的高通量自动化免疫分析仪,但还没有与现有系统进行比较。本研究比较了Architect i2000平台和更新的高通量全自动免疫分析仪之间的乙型肝炎表面抗原、乙型肝炎表面抗体和乙型肝炎总核心抗体分析。

从2018年5月至2018年6月,总共有932、914和1055个样本使用Architect i2000系统在研究中心进行了乙型肝炎表面抗原,乙型肝炎表面抗体和总乙型肝炎核心抗体的常规测试 再次使用Alinity i,Atellica IM和Cobas e801系统。

研究结果显示,乙型肝炎表面抗原、乙型肝炎表面抗体和乙型肝炎核心抗体的系统总符合率分别为98.0%、89.5%和93.0%。科恩的κ值超过0.8。4个系统测定的血清乙型肝炎表面抗体水平之间的相关性均较高(r > 0.85)。Alinity i、Atellica IM和Cobas e801的乙肝表面抗体平均值大于Architect i2000 (P < .001)。

与现有的Architect i2000系统相比,Alinity i、Atellica IM和Cobas e801自动免疫分析仪在检测乙肝病毒感染方面表现良好。然而,新的系统对乙肝表面抗体有更高的滴度和阳性率,而且更敏感。值得注意的是,Atellica IM的乙肝核心抗体总阳性率低于Architect i2000。

原始出处:

Dongju Won, MD; Younhee Park, MD, PhD;Comparison of High-Throughput Fully Automated Immunoanalyzers for Detecting Hepatitis B Virus Infection

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1969443, encodeId=5e3e196944382, content=<a href='/topic/show?id=6532102e6059' target=_blank style='color:#2F92EE;'>#高通量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102760, encryptionId=6532102e6059, topicName=高通量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Tue May 04 20:36:44 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928170, encodeId=c74319281e064, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 08 18:36:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786342, encodeId=717d1e8634271, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 09 19:36:44 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610512, encodeId=47e11610512ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 01 12:36:44 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1969443, encodeId=5e3e196944382, content=<a href='/topic/show?id=6532102e6059' target=_blank style='color:#2F92EE;'>#高通量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102760, encryptionId=6532102e6059, topicName=高通量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Tue May 04 20:36:44 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928170, encodeId=c74319281e064, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 08 18:36:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786342, encodeId=717d1e8634271, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 09 19:36:44 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610512, encodeId=47e11610512ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 01 12:36:44 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1969443, encodeId=5e3e196944382, content=<a href='/topic/show?id=6532102e6059' target=_blank style='color:#2F92EE;'>#高通量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102760, encryptionId=6532102e6059, topicName=高通量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Tue May 04 20:36:44 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928170, encodeId=c74319281e064, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 08 18:36:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786342, encodeId=717d1e8634271, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 09 19:36:44 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610512, encodeId=47e11610512ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 01 12:36:44 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
    2020-11-09 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1969443, encodeId=5e3e196944382, content=<a href='/topic/show?id=6532102e6059' target=_blank style='color:#2F92EE;'>#高通量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102760, encryptionId=6532102e6059, topicName=高通量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Tue May 04 20:36:44 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928170, encodeId=c74319281e064, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Apr 08 18:36:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786342, encodeId=717d1e8634271, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 09 19:36:44 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610512, encodeId=47e11610512ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 01 12:36:44 CST 2020, time=2020-06-01, status=1, ipAttribution=)]